What one share of Semnur Pharmaceuticals holds
We are a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative non-opioid pain management products for the treatment of acute and chronic pain. We believe that our innovative non-opioid product portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients’ lives.
Semnur Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.76 |
|---|---|
| Cash and investments | $0.00 |
| Debt | $0.03 |
| Book value | −$0.13 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$0.02 | — | — | — | −$0.21 |
| 2025 | — | −$0.78 | — | — | — | −$0.09 |
Common questions about Semnur Pharmaceuticals
How much does one share of Semnur Pharmaceuticals earn?
Over the last 12 months, Semnur Pharmaceuticals lost $0.76 for each share.
Does Semnur Pharmaceuticals pay a dividend?
Semnur Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Semnur Pharmaceuticals’s book value per share?
Semnur Pharmaceuticals’s book value is negative (−$0.13 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Semnur Pharmaceuticals have?
Each share of Semnur Pharmaceuticals has $0.00 of cash and investments and $0.03 of debt, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.